{"abstract": "The pharmaceutical giant\u2019s $15 billion purchase of Hospira should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews.", "web_url": "https://dealbook.nytimes.com/2015/02/05/a-deal-that-could-reverse-pfizers-history-of-value-destroying-acquisitions/", "snippet": "The pharmaceutical giant\u2019s $15 billion purchase of Hospira should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews.", "lead_paragraph": "Pfizer has made more than its share of value-destroying acquisitions. The pharmaceutical giant\u2019s $15.2 billion purchase of Hospira could reverse that history. The injectable-drug maker\u2019s strength in non-branded medications should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-articleLarge.jpg", "height": 800, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 800}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-jumbo.jpg", "height": 1024, "width": 768, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-superJumbo.jpg", "height": 2048, "width": 1536, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "A Deal That Could Reverse Pfizer\u2019s History of Value-Destroying Acquisitions", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology and Bioengineering", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Hospira Inc", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Warner-Lambert Co", "rank": 7, "major": "N"}], "pub_date": "2015-02-05T19:10:05+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/cd398e20-7b2f-5253-bf0a-cf664131cecc", "word_count": 383, "uri": "nyt://article/cd398e20-7b2f-5253-bf0a-cf664131cecc"}